CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Average Target Price from Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $5.77.

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Monday, November 11th.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $1.13 on Friday. CytomX Therapeutics has a 52-week low of $0.83 and a 52-week high of $5.85. The company has a market capitalization of $88.43 million, a PE ratio of 6.65 and a beta of 1.07. The company has a fifty day moving average of $1.06 and a 200-day moving average of $1.19.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $33.43 million during the quarter, compared to analyst estimates of $18.92 million. During the same quarter last year, the business earned $0.04 EPS. On average, equities analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Trading of CytomX Therapeutics

Several large investors have recently modified their holdings of CTMX. Jacobs Levy Equity Management Inc. boosted its position in shares of CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares in the last quarter. US Bancorp DE purchased a new stake in shares of CytomX Therapeutics in the third quarter valued at about $40,000. Geode Capital Management LLC increased its stake in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 34,032 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after acquiring an additional 37,739 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.